公开(公告)号：US20240424105A1

公开(公告)日：2024-12-26

申请号：US18736363

申请日：2024-06-06

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： Muthiah Manoharan ,  Muthusamy Jayaraman ,  Kallanthottathil G. Rajeev ,  Laxman Eltepu ,  Steven Ansell ,  Jianxin Chen

IPC: A61K47/44 ,  A61K9/127 ,  A61K31/7088 ,  A61K31/713 ,  A61K39/00 ,  A61K39/39 ,  A61K47/10 ,  A61K47/18 ,  A61K47/20 ,  A61K47/28 ,  C07C229/08 ,  C07C229/30 ,  C07C237/16 ,  C07C251/38 ,  C07C251/78 ,  C07C271/12 ,  C07C271/20 ,  C07C323/25 ,  C07D203/10 ,  C07D317/28 ,  C07D317/44 ,  C07D317/46 ,  C07D317/72 ,  C07D319/06 ,  C07D405/12 ,  C07D491/056 ,  C07D491/113 ,  C12N15/11 ,  C12N15/113

Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).

公开(公告)号：US12129467B2

公开(公告)日：2024-10-29

申请号：US18410136

申请日：2024-01-11

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： Ed Yaworski ,  Lloyd B. Jeffs ,  Lorne R. Palmer

IPC: C07H21/04 ,  A61K9/107 ,  A61K9/50 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/712 ,  A61K31/713 ,  A61K47/14 ,  A61K47/54 ,  C12N15/113 ,  C12N15/88 ,  A61K9/127

CPC classification number: C12N15/113 ,  A61K9/1075 ,  A61K9/5015 ,  A61K9/5123 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/712 ,  A61K31/713 ,  A61K47/14 ,  A61K47/543 ,  C12N15/88 ,  A61K9/1272 ,  A61K9/1274 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/3515 ,  C12N2320/32

Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.

公开(公告)号：US20240316206A1

公开(公告)日：2024-09-26

申请号：US18646429

申请日：2024-04-25

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： Ed Yaworski ,  Stephen Reid ,  James Heyes ,  Adam Judge ,  Ian MacLachlan

IPC: A61K47/44 ,  A61K9/00 ,  A61K9/127 ,  A61K31/713 ,  A61K47/54 ,  C12N15/11 ,  C12N15/113 ,  C12N15/88

CPC classification number: A61K47/44 ,  A61K9/0019 ,  A61K9/1272 ,  A61K31/713 ,  A61K47/543 ,  C12N15/111 ,  C12N15/1137 ,  C12N15/88 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/344 ,  C12N2320/30 ,  C12N2320/32

Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.

公开(公告)号：US12043833B2

公开(公告)日：2024-07-23

申请号：US17854575

申请日：2022-06-30

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： James Heyes ,  Richard J. Holland ,  Adam Judge ,  Amy C. H. Lee ,  Alan D. Martin ,  Nicholas Michael Snead ,  Emily P. Thi ,  Mark Wood ,  Xin Ye

IPC: C12N15/113

CPC classification number: C12N15/1131 ,  C12N2310/14 ,  C12N2310/344 ,  C12N2310/346 ,  C12N2310/3515

Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

公开(公告)号：US12037587B2

公开(公告)日：2024-07-16

申请号：US18410136

申请日：2024-01-11

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： Ed Yaworski ,  Lloyd B. Jeffs ,  Lorne R. Palmer

IPC: C07H21/04 ,  A61K9/107 ,  A61K9/50 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/712 ,  A61K31/713 ,  A61K47/14 ,  A61K47/54 ,  C12N15/113 ,  C12N15/88 ,  A61K9/127

CPC classification number: C12N15/113 ,  A61K9/1075 ,  A61K9/5015 ,  A61K9/5123 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/712 ,  A61K31/713 ,  A61K47/14 ,  A61K47/543 ,  C12N15/88 ,  A61K9/1272 ,  A61K9/1274 ,  C12N2310/14 ,  C12N2310/321 ,  C12N2310/3515 ,  C12N2320/32

Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.

公开(公告)号：US11904052B2

公开(公告)日：2024-02-20

申请号：US17749657

申请日：2022-05-20

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： Jeffrey P. Bechard ,  Wayne J. Wallis

IPC: A61K9/127 ,  A61P29/00 ,  A61K9/00 ,  A61K31/192 ,  A61K47/10 ,  A61K47/24 ,  C12N15/11 ,  A61K45/06

CPC classification number: A61K9/127 ,  A61K9/0019 ,  A61K31/192 ,  A61K47/10 ,  A61K47/24 ,  A61P29/00 ,  C12N15/111 ,  A61K45/06

Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.

公开(公告)号：US20230110295A1

公开(公告)日：2023-04-13

申请号：US17854575

申请日：2022-06-30

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： James HEYES ,  Richard J. HOLLAND ,  Adam JUDGE ,  Amy C. H. LEE ,  Alan D. MARTIN ,  Nicholas Michael SNEAD ,  Emily P. THI ,  Mark WOOD ,  Xin YE

IPC: C12N15/113

Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

公开(公告)号：US20230060006A1

公开(公告)日：2023-02-23

申请号：US17749657

申请日：2022-05-20

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： Jeffrey P. BECHARD ,  Wayne J. WALLIS

IPC: A61K9/127 ,  A61K9/00 ,  A61K47/24 ,  C12N15/11 ,  A61P29/00 ,  A61K47/10 ,  A61K31/192 ,  A61K45/06

Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.

公开(公告)号：US11446383B2

公开(公告)日：2022-09-20

申请号：US16109130

申请日：2018-08-22

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： Ed Yaworski ,  Stephen Reid ,  James Heyes ,  Adam Judge ,  Ian MacLachlan

IPC: C07H21/02 ,  C07H21/04 ,  A61K47/44 ,  A61K9/00 ,  A61K9/127 ,  A61K31/713 ,  C12N15/11 ,  C12N15/88 ,  A61K47/54 ,  C12N15/113

Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.

公开(公告)号：US20220133636A1

公开(公告)日：2022-05-05

申请号：US17291873

申请日：2019-11-08

Applicant: ARBUTUS BIOPHARMA CORPORATION

Inventor： Michael J. ABRAMS ,  James HEYES ,  Richard J. HOLLAND ,  Kieu Mong LAM ,  Mark WOOD

IPC: A61K9/51 ,  A61K31/713 ,  C12N15/113 ,  C07F7/18

Abstract: Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R1, R2, R3 and R4 are defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.